Chugai Pharmaceutical stock: Results arrive October 27, 2026 for Chugai Pharmaceutical stock

Published on 10/21/2026 at 16:52 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Chugai received the Porter Prize on October 16, 2026. Chugai Pharmaceutical stock costs EUR 36.73 on October 21, 2026 at 4:39 p.m. CEST.

Reporting date October 27, 2026

Chugai Pharmaceutical scheduled third-quarter results for October 27, 2026.
Second-quarter revenue reached JPY 341.58 billion and net income JPY 116.33 billion.
Chugai Pharmaceutical stock costs EUR 36.73 at Lang & Schwarz on October 21, 2026 at 4:39 p.m. CEST.
The Tokyo listing had a price-to-earnings ratio of 22.73 and a JPY 10.7 trillion market capitalization.

Chugai Pharmaceutical, JP3519400000, Illustration mit AI erstellt.

Chugai Pharmaceutical (ISIN JP3519400000) has scheduled its fiscal 2026 third-quarter results for October 27, 2026, giving investors a defined date for the next operating update. The company received the Porter Prize 2026 on October 16, recognizing its drug discovery strategy and Roche alliance, according to Chugai Pharmaceutical. At Lang & Schwarz, the stock was trading at EUR 36.73 on October 21, 2026 at 4:39 p.m. CEST.

October 27 brings the next test

Chugai's investor-relations calendar lists the third-quarter results for the January to September 2026 period on October 27, 2026 at 5:00 p.m. JST, followed by a results conference at 6:00 p.m. JST. The schedule is published on Chugai Pharmaceutical.

The latest reported quarter provides the operating benchmark. Revenue reached JPY 341.58 billion in the second quarter of fiscal 2026, while net income stood at JPY 116.33 billion, according to JPX Explorer. First-quarter revenue was JPY 321.75 billion, making the second-quarter figure JPY 19.84 billion higher on a sequential basis.

Tokyo valuation sets the frame

Chugai's Tokyo listing last stood at JPY 6,511 on October 21, 2026 at 3:30 p.m. JST, up 1.26 percent from the prior session in the home market. Its 52-week range was JPY 5,974.00 to JPY 10,700.00, with a trading volume of 3,356,000 shares. The price-to-earnings ratio was 22.73 and the dividend yield was 0.03 percent.

The Tokyo listing carried a market capitalization of JPY 10.7 trillion on October 21, 2026. For comparison, Takeda Pharmaceutical traded at JPY 6,315.00 with a price-to-earnings ratio of 56.29 and a JPY 10.0 trillion market capitalization, while Daiichi Sankyo traded at JPY 2,841.00 with a price-to-earnings ratio of 21.52 and a JPY 5.2 trillion market capitalization.

What the next report could clarify

The October 27 release will update the nine-month revenue and earnings picture after the JPY 341.58 billion second-quarter revenue figure. It will also give investors a fresh reading on the balance between Chugai's proprietary drug discovery programs and its Roche alliance, the strategy recognized by the Porter Prize announcement.

Stock price and scheduled date

The scheduled results date is the clearest near-term calendar marker, while the Tokyo valuation places Chugai in line with Daiichi Sankyo on price-to-earnings measures. At Lang & Schwarz, Chugai Pharmaceutical stock was trading at EUR 36.73 on October 21, 2026 at 4:39 p.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of Chugai Pharmaceutical stock.